PMID- 37005303
OWN - NLM
STAT- MEDLINE
DCOM- 20230404
LR  - 20230404
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 46
IP  - 4
DP  - 2023
TI  - Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes 
      Mellitus in Japan from 2012-2020: a Time-Series Analysis.
PG  - 592-598
LID - 10.1248/bpb.b22-00710 [doi]
AB  - In April 2014, sodium-glucose cotransporter 2 inhibitor (SGLT-2i) was introduced 
      in Japan. In May 2015, the prescription limitation for SGLT-2i was lifted. 
      Subsequently, SGLT-2i was shown to reduce cardiovascular events in patients with 
      type 2 diabetes mellitus (T2DM). SGLT-2i prescription is expected to increase and 
      consequently affect the prescription trends for other antidiabetic agents. 
      Therefore, we evaluated the trends for antidiabetic agent prescriptions in Japan 
      from April 2012 to March 2020. In this study, a dynamic cohort consisting of 
      patients with T2DM derived from the Japan Medical Data Center health insurance 
      database and with at least one antidiabetic agent prescription was investigated. 
      The prescription rates were calculated monthly (/1000 person-months) for each 
      class of antidiabetic agent. The eligible cohort comprised 34333 patients. The 
      prescription rate for dipeptidyl peptidase-4 inhibitor increased from 424.0 in 
      April 2012 to 656.3 in May 2015, and slightly decreased to 635.4 in March 2020. 
      The prescription rate for biguanide consistently increased from 347.2 in April 
      2012 to 500.1 in March 2020. The prescription rate for sulfonylurea consistently 
      decreased from 393.8 in April 2012 to 172.5 in March 2020. The prescription rate 
      for SGLT-2i consistently increased from 4.1 in April 2014 to 363.1 in March 2020. 
      SGLT-2i prescription increased and may affect the prescription trends for 
      dipeptidyl peptidase-4 inhibitor and sulfonylurea after May 2015, when the 
      prescription limitation for SGLT-2i was lifted. Biguanide prescriptions increased 
      regardless of the introduction of SGLT-2i. The treatment of T2DM in Japan is 
      clearly changing, with a focus on SGLT-2i and biguanide.
FAU - Iketani, Ryo
AU  - Iketani R
AD  - Center for Outcomes Research and Economic Evaluation for Health, National 
      Institute of Public Health.
FAU - Imai, Shinobu
AU  - Imai S
AD  - Division of Pharmacoepidemiology, Department of Healthcare and Regulatory 
      Sciences, School of Pharmacy, Showa University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Biguanides)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
SB  - IM
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use/pharmacology
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Japan
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/pharmacology
MH  - *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Sulfonylurea Compounds
MH  - Prescriptions
MH  - Biguanides/therapeutic use
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
OTO - NOTNLM
OT  - administrative claims data
OT  - antidiabetic agent
OT  - sodium-glucose cotransporter-2 inhibitor
OT  - time-series analysis
OT  - type 2 diabetes mellitus
EDAT- 2023/04/03 06:00
MHDA- 2023/04/04 06:42
CRDT- 2023/04/02 22:34
PHST- 2023/04/04 06:42 [medline]
PHST- 2023/04/02 22:34 [entrez]
PHST- 2023/04/03 06:00 [pubmed]
AID - 10.1248/bpb.b22-00710 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2023;46(4):592-598. doi: 10.1248/bpb.b22-00710.